Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q4827853> ?p ?o }
Showing triples 1 to 64 of
64
with 100 triples per page.
- Q4827853 subject Q22695562.
- Q4827853 subject Q8301163.
- Q4827853 subject Q8400978.
- Q4827853 subject Q8403600.
- Q4827853 subject Q8760194.
- Q4827853 abstract "Avax Technologies, Inc (Template:OTCPink) is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007 [1]. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).".
- Q4827853 industry Q864601.
- Q4827853 keyPerson Q140686.
- Q4827853 keyPerson Q484876.
- Q4827853 locationCity Q1345.
- Q4827853 locationCountry Q30.
- Q4827853 service Q2378309.
- Q4827853 type Q891723.
- Q4827853 wikiPageExternalLink www.avax-tech.com.
- Q4827853 wikiPageExternalLink index.php.
- Q4827853 wikiPageExternalLink group.php?v=app_2373072738&ref=mf&gid=254690660179.
- Q4827853 wikiPageExternalLink index.htm.
- Q4827853 wikiPageWikiLink Q1345.
- Q4827853 wikiPageWikiLink Q140686.
- Q4827853 wikiPageWikiLink Q142.
- Q4827853 wikiPageWikiLink Q172341.
- Q4827853 wikiPageWikiLink Q180614.
- Q4827853 wikiPageWikiLink Q209226.
- Q4827853 wikiPageWikiLink Q22695562.
- Q4827853 wikiPageWikiLink Q2378309.
- Q4827853 wikiPageWikiLink Q30.
- Q4827853 wikiPageWikiLink Q3658562.
- Q4827853 wikiPageWikiLink Q456.
- Q4827853 wikiPageWikiLink Q484876.
- Q4827853 wikiPageWikiLink Q506441.
- Q4827853 wikiPageWikiLink Q5256667.
- Q4827853 wikiPageWikiLink Q5425274.
- Q4827853 wikiPageWikiLink Q7108.
- Q4827853 wikiPageWikiLink Q780226.
- Q4827853 wikiPageWikiLink Q8301163.
- Q4827853 wikiPageWikiLink Q8400978.
- Q4827853 wikiPageWikiLink Q8403600.
- Q4827853 wikiPageWikiLink Q8563477.
- Q4827853 wikiPageWikiLink Q864601.
- Q4827853 wikiPageWikiLink Q8760194.
- Q4827853 wikiPageWikiLink Q891723.
- Q4827853 wikiPageWikiLink Q896666.
- Q4827853 homepage www.avax-tech.com.
- Q4827853 homepage index.htm.
- Q4827853 industry Q864601.
- Q4827853 keyPeople "Richard Rainey".
- Q4827853 locationCity Q1345.
- Q4827853 locationCountry Q30.
- Q4827853 name "Avax Technologies".
- Q4827853 services Q2378309.
- Q4827853 type Q891723.
- Q4827853 type Organization.
- Q4827853 type Agent.
- Q4827853 type Company.
- Q4827853 type Organisation.
- Q4827853 type Agent.
- Q4827853 type SocialPerson.
- Q4827853 type Thing.
- Q4827853 type Q43229.
- Q4827853 comment "Avax Technologies, Inc (Template:OTCPink) is a Philadelphia based biotechnology company whose most advanced product candidate is MVax for melanoma. MVax is a cancer vaccine that received a Special Protocol Assessment agreement with the FDA in October 2006, and subsequently began a Phase III registration clinical trial in November 2007 [1]. In previous studies, MVax demonstrated a 5-year overall survival rate (OS)of 44% and response rate of 35% (13% CR, 22% PR).".
- Q4827853 label "Avax Technologies".
- Q4827853 homepage www.avax-tech.com.
- Q4827853 homepage index.htm.
- Q4827853 name "Avax Technologies".